![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-Logo20icrowd-1.png\")
<\/p>\n<\/p>\n
DelveInsight’s “<\/span>Phenylketonuria (PKU) Market Insights Report<\/strong><\/a>” offers a detailed analysis of the disease, its causes, symptoms, diagnostics, modalities, and treatment options. <\/span><\/p>\n The <\/span>Phenylketonuria market report<\/strong> also covers Phenylketonuria market size, epidemiology, developing medicines, market drivers, market hurdles, ongoing clinical studies, significant partnerships in the sector, and key pharmaceutical companies actively driving the Phenylketonuria market size forward.<\/span><\/p>\n Some of the key highlights from the <\/strong>Phenylketonuria Market<\/strong><\/a> Insights: <\/strong><\/p>\n Learn more by requesting for sample @ <\/strong>Phenylketonuria Market Landscape<\/strong><\/a> <\/strong><\/p>\n Phenylketonuria: Overview <\/strong><\/p>\n Phenylketonuria is a metabolic disorder that can be detected during the first few days of life through regular newborn screening. The enzyme phenylalanine hydroxylase (PAH), which is responsible for digesting the amino acid phenylalanine, is absent or deficient in Phenylketonuria.<\/span><\/p>\n Proteins’ chemical building blocks, amino acids, are required for normal growth and development. Phenylalanine is metabolized to tyrosine in the presence of normal PAH activity. When PAH is missing or insufficient, phenylalanine builds up and becomes toxic to the brain.<\/span><\/p>\n Most patients with Phenylketonuria would have a serious intellectual handicap if they were not treated. Treatment begins during the early days or weeks of infancy with a carefully managed, phenylalanine-restricted diet to prevent intellectual impairment.<\/span><\/p>\n For more insights into Disease, causes, and treatment, reach out @ <\/strong>Phenylketonuria Treatment Landscape<\/strong><\/a> <\/strong><\/p>\n Phenylketonuria Epidemiology Segmentation <\/strong><\/p>\n The <\/span>Phenylketonuria Market report <\/strong>proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:<\/span><\/p>\n Visit for more @ <\/strong>Phenylketonuria Epidemiological Insights<\/strong><\/a> <\/strong><\/p>\n Phenylketonuria Market <\/strong><\/p>\n There is currently no cure for phenylketonuria, however, the most common treatment is a dietary restriction of phenylalanine to the bare minimum required for proper growth, supplemented with specially tailored medical meals.<\/span><\/p>\n For many years, the only treatment for Phenylketonuria was to follow a strict low-phenylalanine diet for the rest of one’s life. As a result, the primary line of treatment for Phenylketonuria is dietary therapy, which begins soon after diagnosis and consists of a low Phe diet supplemented with amino acid formulations.<\/span><\/p>\n The goal of Phenylketonuria treatment is to keep plasma phenylalanine levels between 120 and 360 mol\/L (2–6 mg\/dL), which can be accomplished with a properly designed and supervised diet. Because phenylalanine is an important amino acid, it should be limited in the child’s diet. A well-balanced diet can help people avoid intellectual handicaps, as well as neurological, behavioral, and dermatological issues.<\/span><\/p>\n Pharmaceutical companies’ extensive research and development activities, already approved therapies, and expanding prevalence will all contribute to the growth of the Phenylketonuria market.<\/span><\/p>\n Phenylketonuria Pipeline Therapies and Key Companies <\/strong><\/p>\n For more information, visit <\/strong>Phenylketonuria Market Analysis, Patient Pool and Emerging Therapies<\/strong><\/a> <\/strong><\/p>\n Phenylketonuria Market Drivers <\/strong><\/p>\n Scope of the Report<\/strong><\/p>\n Key Questions Answered in the Report<\/strong><\/p>\n Get in touch with our Business executive @ <\/strong>Phenylketonuria Market Landscape Analysis<\/strong><\/a> <\/strong><\/p>\n Table of Contents <\/strong><\/p>\n Learn more about the report offerings @ <\/strong>Phenylketonuria Market Outlook<\/strong><\/a><\/p>\n Related Reports:<\/strong><\/p>\n Phenylketonuria Epidemiology<\/strong><\/a><\/p>\n DelveInsight’s ‘Phenylketonuria—Epidemiology Forecast–2030’ report.<\/strong><\/p>\n Phenylketonuria Pipeline<\/strong><\/a><\/p>\n DelveInsight’s, “Phenylketonuria – Pipeline Insight, 2021,” report.<\/strong><\/p>\n Latest Reports: <\/strong><\/p>\n![\"Phenylketonuria](\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Phenylketonuria%20(PKU)%20Market%20Insights.jpg?1628570711865\")
<\/p>\n\n
\n
\n
\n
\n
\n
\n\n
\n 1.<\/td>\n Key Insights<\/span><\/td>\n<\/tr>\n \n 2.<\/td>\n Report Introduction<\/span><\/td>\n<\/tr>\n \n 3.<\/td>\n Phenylketonuria<\/span> Competitive Intelligence Analysis<\/span><\/td>\n<\/tr>\n \n 4.<\/td>\n Phenylketonuria<\/span> Market Overview at a Glance<\/span><\/td>\n<\/tr>\n \n 5.<\/td>\n Phenylketonuria<\/span> Executive Summary<\/span><\/td>\n<\/tr>\n \n 6.<\/td>\n Phenylketonuria<\/span> Epidemiology and Market Methodology<\/span><\/td>\n<\/tr>\n \n 7.<\/td>\n Phenylketonuria<\/span> Epidemiology and Patient Population<\/span><\/td>\n<\/tr>\n \n 8.<\/td>\n Phenylketonuria<\/span> Patient Journey<\/span><\/td>\n<\/tr>\n \n 9.<\/td>\n Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/td>\n<\/tr>\n \n 10.<\/td>\n Key Endpoints in <\/span>Phenylketonuria<\/span> Clinical Trials<\/span><\/td>\n<\/tr>\n \n 11.<\/td>\n Phenylketonuria Marketed Therapies<\/span><\/td>\n<\/tr>\n \n 12.<\/td>\n Phenylketonuria Emerging Therapies<\/span><\/td>\n<\/tr>\n \n 13.<\/td>\n Phenylketonuria: 7 Major Market Analysis<\/span><\/td>\n<\/tr>\n \n 14.<\/td>\n Attribute analysis<\/span><\/td>\n<\/tr>\n \n 15.<\/td>\n Phenylketonuria Access and Reimbursement Overview<\/span><\/td>\n<\/tr>\n \n 16.<\/td>\n KOL Reviews<\/span><\/td>\n<\/tr>\n \n 17.<\/td>\n Case Reports<\/span><\/td>\n<\/tr>\n \n 18.<\/td>\n Phenylketonuria Market Drivers<\/span><\/td>\n<\/tr>\n \n 19.<\/td>\n Phenylketonuria Market Barriers<\/span><\/td>\n<\/tr>\n \n 20.<\/td>\n SWOT Analysis<\/span><\/td>\n<\/tr>\n \n 21.<\/td>\n Disclaimer<\/span><\/td>\n<\/tr>\n \n 22.<\/td>\n DelveInsight Capabilities<\/span><\/td>\n<\/tr>\n \n 23.<\/td>\n About DelveInsight<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n